Novel therapeutics for gastro–esophageal reflux symptoms

References

• Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol. 101(8), 1900–20; quiz 1943 (2006).
   PubMed Web of Science ®Google Scholar
• Vaezi MF, Singh S, Richter JE. Role of acid and duodenogastric reflux in esophageal mucosal injury: a review of animal and human studies. Gastroenterology 108(6), 1897–1907 (1995).
   PubMed Web of Science ®Google Scholar
• Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112(6), 1798–1810 (1997).
   PubMed Web of Science ®Google Scholar
• Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 58(2), 295–309 (2009).
   PubMed Web of Science ®Google Scholar
• Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro–oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment. Pharmacol. Ther. 11(4), 765–773 (1997).
   PubMed Web of Science ®Google Scholar
• Tack J, Fass R. Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder? Aliment. Pharmacol. Ther. 19(Suppl. 1), 28–34 (2004).
   PubMed Web of Science ®Google Scholar
• Lundell L. Surgical therapy of gastro–oesophageal reflux disease. Best Pract. Res. Clin. Gastroenterol. 24(6), 947–959 (2010).
   PubMed Web of Science ®Google Scholar
• Mainie I, Tutuian R, Shay S et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 55(10), 1398–1402 (2006).
   PubMed Web of Science ®Google Scholar
• Zerbib F, Roman S, Ropert A et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am. J. Gastroenterol. 101(9), 1956–1963 (2006).
   PubMed Web of Science ®Google Scholar
• Dent J, Holloway RH, Toouli J, Dodds WJ. Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux. Gut 29(8), 1020–1028 (1988).
   PubMed Web of Science ®Google Scholar
• Sifrim D, Holloway R, Silny J, Tack J, Lerut A, Janssens J. Composition of the postprandial refluxate in patients with gastroesophageal reflux disease. Am. J. Gastroenterol. 96(3), 647–655 (2001).
   PubMed Web of Science ®Google Scholar
• Mittal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J. Transient lower esophageal sphincter relaxation. Gastroenterology 109(2), 601–610 (1995).
   PubMed Web of Science ®Google Scholar
• Bredenoord AJ, Draaisma WA, Weusten BL, Gooszen HG, Smout AJ. Mechanisms of acid, weakly acidic and gas reflux after anti-reflux surgery. Gut 57(2), 161–166 (2008).
   PubMed Web of Science ®Google Scholar
• Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 118(1), 7–13 (2000).
   PubMed Web of Science ®Google Scholar
• Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro–oesophageal reflux disease. Gut 50(1), 19–24 (2002).
   PubMed Web of Science ®Google Scholar
• Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro–oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment. Pharmacol. Ther. 17(2), 243–251 (2003).
   PubMed Web of Science ®Google Scholar
• Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro–oesophageal reflux disease. Gut 52(4), 464–470 (2003).
   PubMed Web of Science ®Google Scholar
• Cossentino MJ, Mann K, Armbruster SP, Lake JM, Maydonovitch C, Wong RK. Randomised clinical trial: the effect of baclofen in patients with gastro–oesophageal reflux - a randomised prospective study. Aliment. Pharmacol. Ther. doi:10.1111/j.1365-2036.2012.05068.x (2012).
   Google Scholar
• Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro–oesophageal reflux refractory to proton pump inhibitors. Gut 52(10), 1397–1402 (2003).
   PubMed Web of Science ®Google Scholar
• Gerson LB, Huff FJ, Hila A et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am. J. Gastroenterol. 105(6), 1266–1275 (2010).
   PubMed Web of Science ®Google Scholar
• Vakil NB, Huff FJ, Bian A, Jones DS, Stamler D. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study. Am. J. Gastroenterol. 106(8), 1427–1438 (2011).
   PubMed Web of Science ®Google Scholar
• Boeckxstaens GE, Rydholm H, Lei A, Adler J, Ruth M. Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects. Aliment. Pharmacol. Ther. 31(11), 1208–1217 (2010).
   PubMed Web of Science ®Google Scholar
• Boeckxstaens GE, Beaumont H, Mertens V et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 139(2), 409–417 (2010).
   PubMed Web of Science ®Google Scholar
• Boeckxstaens GE, Beaumont H, Hatlebakk JG et al. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. Gut 60(9), 1182–1188 (2011).
   PubMed Web of Science ®Google Scholar
• Hornby PJ. Receptors and transmission in the brain–gut axis. II. Excitatory amino acid receptors in the brain–gut axis. Am. J. Physiol. Gastrointest. Liver Physiol. 280(6), G1055–G1060 (2001).
   PubMed Web of Science ®Google Scholar
• Page AJ, Young RL, Martin CM et al. Metabotropic glutamate receptors inhibit mechanosensitivity in vagal sensory neurons. Gastroenterology 128(2), 402–410 (2005).
   PubMed Web of Science ®Google Scholar
• Jensen J, Lehmann A, Uvebrant A et al. Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. Eur. J. Pharmacol. 519(1–2), 154–157 (2005).
   PubMed Web of Science ®Google Scholar
• Frisby CL, Mattsson JP, Jensen JM, Lehmann A, Dent J, Blackshaw LA. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology 129(3), 995–1004 (2005).
   PubMed Web of Science ®Google Scholar
• Keywood C, Wakefield M, Tack J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro–oesophageal reflux disease. Gut 58(9), 1192–1199 (2009).
   PubMed Web of Science ®Google Scholar
• Zerbib F, Keywood C, Strabach G. Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pH-impedance study in healthy subjects. Neurogastroenterol. Motil. 22(8), 859–65, e231 (2010).
   PubMed Web of Science ®Google Scholar
• Zerbib F, Bruley des Varannes S, Roman S et al. Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro–oesophageal reflux disease. Aliment. Pharmacol. Ther. 33(8), 911–921 (2011).
   PubMed Web of Science ®Google Scholar
• Castell DO, Zerbib F, Bruley Des Varannes S et al. Efficacy and tolerability of ADX10059, a mGluR5 negative allosteric modulator, as add on therapy to proton pump inhibitors (PPIs) in patients with gastroesophageal reflux disease (GERD). Gastroenterology 140, S577 (2011).
   Google Scholar
• Rohof WO, Lei A, Hirsch DP et al. The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. Aliment. Pharmacol. Ther. 35(10), 1231–1242 (2012).
   PubMed Web of Science ®Google Scholar
• Hirsch DP, Holloway RH, Tytgat GN, Boeckxstaens GE. Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology 115(6), 1374–1380 (1998).
   PubMed Web of Science ®Google Scholar
• Hirsch DP, Tiel-Van Buul MM, Tytgat GN, Boeckxstaens GE. Effect of l-NMMA on postprandial transient lower esophageal sphincter relaxations in healthy volunteers. Dig. Dis. Sci. 45(10), 2069–2075 (2000).
   PubMedGoogle Scholar
• Boeckxstaens GE, Hirsch DP, Fakhry N, Holloway RH, D’Amato M, Tytgat GN. Involvement of cholecystokininA receptors in transient lower esophageal sphincter relaxations triggered by gastric distension. Am. J. Gastroenterol. 93(10), 1823–1828 (1998).
   PubMed Web of Science ®Google Scholar
• Zerbib F, Bruley Des Varannes S, Scarpignato C et al. Endogenous cholecystokinin in postprandial lower esophageal sphincter function and fundic tone in humans. Am. J. Physiol. 275(6 Pt 1), G1266–G1273 (1998).
   Google Scholar
• Trudgill NJ, Hussain FN, Moustafa M, Ajjan R, D’Amato M, Riley SA. The effect of cholecystokinin antagonism on postprandial lower oesophageal sphincter function in asymptomatic volunteers and patients with reflux disease. Aliment. Pharmacol. Ther. 15(9), 1357–1364 (2001).
   PubMedGoogle Scholar
• Penagini R, Bianchi PA. Effect of morphine on gastroesophageal reflux and transient lower esophageal sphincter relaxation. Gastroenterology 113(2), 409–414 (1997).
   PubMed Web of Science ®Google Scholar
• Beaumont H, Jensen J, Carlsson A, Ruth M, Lehmann A, Boeckxstaens G. Effect of Δ9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br. J. Pharmacol. 156(1), 153–162 (2009).
   PubMed Web of Science ®Google Scholar
• Jafri SM, Arora G, Triadafilopoulos G. What is left of the endoscopic antireflux devices? Curr. Opin. Gastroenterol. 25(4), 352–357 (2009).
   PubMedGoogle Scholar
• Tam WC, Schoeman MN, Zhang Q et al. Delivery of radiofrequency energy to the lower oesophageal sphincter and gastric cardia inhibits transient lower oesophageal sphincter relaxations and gastro–oesophageal reflux in patients with reflux disease. Gut 52(4), 479–485 (2003).
   PubMed Web of Science ®Google Scholar
• Corley DA, Katz P, Wo JM et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology 125(3), 668–676 (2003).
   PubMed Web of Science ®Google Scholar
• Coron E, Sebille V, Cadiot G et al.; Consortium de Recherche Indépendant sur le Traitement et L’exploration du Reflux Gastro–oesophagien et de L’endobrachyoesophage (CRITERE). Clinical trial: radiofrequency energy delivery in proton pump inhibitor-dependent gastro–oesophageal reflux disease patients. Aliment. Pharmacol. Ther. 28(9), 1147–1158 (2008).
   PubMed Web of Science ®Google Scholar
• Arts J, Sifrim D, Rutgeerts P, Lerut A, Janssens J, Tack J. Influence of radiofrequency energy delivery at the gastroesophageal junction (the Stretta procedure) on symptoms, acid exposure, and esophageal sensitivity to acid perfusion in gastroesophagal reflux disease. Dig. Dis. Sci. 52(9), 2170–2177 (2007).
   PubMed Web of Science ®Google Scholar
• Frazzoni M, Conigliaro R, Manta R, Melotti G. Reflux parameters as modified by EsophyX or laparoscopic fundoplication in refractory GERD. Aliment. Pharmacol. Ther. 34(1), 67–75 (2011).
   PubMedGoogle Scholar
• Barnes WE, Hoddinott KM, Mundy S, Williams M. Transoral incisionless fundoplication offers high patient satisfaction and relief of therapy-resistant typical and atypical symptoms of GERD in community practice. Surg. Innov. 18(2), 119–129 (2011).
   Google Scholar
• Bredenoord AJ, Weusten BL, Curvers WL, Timmer R, Smout AJ. Determinants of perception of heartburn and regurgitation. Gut 55(3), 313–318 (2006).
   PubMed Web of Science ®Google Scholar
• Zerbib F, Duriez A, Roman S, Capdepont M, Mion F. Determinants of gastro–oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 57(2), 156–160 (2008).
   PubMed Web of Science ®Google Scholar
• Tutuian R, Vela MF, Hill EG, Mainie I, Agrawal A, Castell DO. Characteristics of symptomatic reflux episodes on Acid suppressive therapy. Am. J. Gastroenterol. 103(5), 1090–1096 (2008).
   PubMed Web of Science ®Google Scholar
• Sharma P, Shaheen NJ, Perez MC et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation–results from two randomized controlled studies. Aliment. Pharmacol. Ther. 29(7), 731–741 (2009).
   PubMed Web of Science ®Google Scholar
• Dent J, Kahrilas PJ, Hatlebakk J et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am. J. Gastroenterol. 103(1), 20–26 (2008).
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Dent J, Lauritsen K et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin. Gastroenterol. Hepatol. 5(12), 1385–1391 (2007).
   PubMed Web of Science ®Google Scholar
• Galmiche JP, Clouse RE, Bálint A et al. Functional esophageal disorders. Gastroenterology 130(5), 1459–1465 (2006).
   PubMed Web of Science ®Google Scholar
• Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut 57(5), 674–683 (2008).
   PubMed Web of Science ®Google Scholar
• Reddy H, Staahl C, Arendt-Nielsen L, Gregersen H, Drewes AM, Funch-Jensen P. Sensory and biomechanical properties of the esophagus in non-erosive reflux disease. Scand. J. Gastroenterol. 42(4), 432–440 (2007).
   PubMed Web of Science ®Google Scholar
• Viazis N, Keyoglou A, Kanellopoulos AK et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am. J. Gastroenterol. doi:10.1038/ajg.2011.179 (2011) (Epub ahead of print).
   Google Scholar
• Miner PB Jr, Rodriguez-Stanley S, Proskin HM, Kianifard F, Bottoli I. Tegaserod in patients with mechanical sensitivity and overlapping symptoms of functional heartburn and functional dyspepsia. Curr. Med. Res. Opin. 24(8), 2159–2172 (2008).
   PubMed Web of Science ®Google Scholar
• Krarup AL, Ny L, Astrand M et al. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment. Pharmacol. Ther. 33(10), 1113–1122 (2011).
   PubMed Web of Science ®Google Scholar
• Caviglia R, Ribolsi M, Maggiano N et al. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am. J. Gastroenterol. 100(3), 543–548 (2005).
   PubMed Web of Science ®Google Scholar
• Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 128(3), 771–778 (2005).
   PubMed Web of Science ®Google Scholar
• van Malenstein H, Farré R, Sifrim D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am. J. Gastroenterol. 103(4), 1021–1028 (2008).
   Google Scholar
• Calabrese C, Bortolotti M, Fabbri A et al. Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am. J. Gastroenterol. 100(3), 537–542 (2005).
   PubMed Web of Science ®Google Scholar
• Vela MF, Craft BM, Sharma N, Freeman J, Hazen-Martin D. Refractory heartburn: comparison of intercellular space diameter in documented GERD vs. functional heartburn. Am. J. Gastroenterol. 106(5), 844–850 (2011).
   PubMed Web of Science ®Google Scholar
• Matysiak-Budnik T, Heyman M, Mégraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment. Pharmacol. Ther. 18(Suppl. 1), 55–62 (2003).
   Google Scholar
• Yoshida N, Kamada K, Tomatsuri N et al. Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole. Dig. Dis. Sci. 55(12), 3393–3398 (2010).
   PubMed Web of Science ®Google Scholar
• Abdulnour-Nakhoul S, Tobey NA, Nakhoul NL, Wheeler SA, Vanegas X, Orlando RC. The effect of tegaserod on esophageal submucosal glands bicarbonate and mucin secretion. Dig. Dis. Sci. 53(9), 2366–2372 (2008).
   Google Scholar
• Majewski M, Jaworski T, Sarosiek I et al. Significant enhancement of esophageal pre-epithelial defense by tegaserod: implications for an esophagoprotective effect. Clin. Gastroenterol. Hepatol. 5(4), 430–438 (2007).
   Google Scholar
• Zerbib F, Belhocine K, Simon M et al. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro–oesophageal reflux disease. Gut 61(4), 501–506 (2012).
   PubMed Web of Science ®Google Scholar
• Nojkov B, Rubenstein JH, Adlis SA et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro–oesophageal reflux disease. Aliment. Pharmacol. Ther. 27(6), 473–482 (2008).
   PubMed Web of Science ®Google Scholar
• Savarino E, Pohl D, Zentilin P et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 58(9), 1185–1191 (2009).
   PubMed Web of Science ®Google Scholar